# Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

> **NCT04144582** · PHASE2 · COMPLETED · sponsor: **Yongchang Zhang** · enrollment: 30 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Sintilimab Combined With Docetaxel Monotherapy

## Key facts

- **NCT ID:** NCT04144582
- **Lead sponsor:** Yongchang Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04144582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04144582, "Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04144582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*